Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial
Retatrutide (development name LY3437943) is an investigational medication developed by Eli Lilly and Company
Hell review your health history and weight loss goals, determine if semaglutide or tirzepatide is right for you, and get you started on a protocol designed to actually work
They are typically given as a once-weekly injection
Regenerative & Cellular Therapies Non-surgical tools like PRF, NAD+, and peptides to alleviate joint pain, exercise and lifestyle recovery, pelvic health, and cellular energy
35Pharma is currently developing HS135, a multi-specific receptor ectodomain ligand trap designed to neutralize activins & GDFs, which according to the company are clinically validated drivers of cardiopulmonary and metabolic disease
